Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™\nPR Newswire\nSAN DIEGO, April 9, 2020\n\n\n\nSAN DIEGO, April 9, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. (\"Kannalife\") (OTCQB: KLFE), has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, \"Atopidine\".\nKannalife chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (\"LEA\"), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for its patented monotherapeutic compound KLS-13022.\n\"Kannalife is a leader of research and development in the field of cannabinoid therapeutics,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"With this new trademark, Kannalife is now utilizing its patented compounds to break into the global skincare products market, which is projected to reach $183.03 billion USD by 2025.\"\nIn pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFα, Il-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (\"COVID-19\").\nThe Company is hoping to ha...